Treatment programme and long‐term outcome in chronic schizophrenia

Acta Psychiatrica Scandinavica

Volumn 82, Issue 358 S, 1990, Pages 151-157

  Kane, J M ^a  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

antipsychotic drugs; chronic schizophrenia; long term treatment; tardive dyskinesia

Indexed keywords

NEUROLEPTIC AGENT;

CONFERENCE PAPER; DRUG RESPONSE; HUMAN; SCHIZOPHRENIA; TARDIVE DYSKINESIA; THEORETICAL STUDY; CHRONIC DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DYSKINESIA; FOLLOW UP; LONG TERM CARE; PSYCHOLOGY; RATING SCALE; REVIEW;

ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; FOLLOW-UP STUDIES; HUMAN; LONG-TERM CARE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0024994877     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1990.tb05309.x     Document Type: Article

References (55)

1. Overview: maintenance therapy in psychiatry I Schizophrenia
2. Important issues in the drug treatment of schizophrenia
3. Maintenance pharmacotherapy in schizophrenia.
4. Maintenance phenothiazine in the aftercare of schizophrenic patients
5. Phenothiazines in the prevention of psychiatric hospitalization. II. Duration of treatment exposure
6. Phenothiazines in the prevention of psychiatric hospitalization. III. Delay or prevention of hospitalization.
7. Phenothiazines in prevention of psychiatric hospitalization. IV. Delay or prevention of hospitalization ‐ a reevaluation.
8. Trial of maintenance therapy in schizophrenia
9. Outpatient maintenance of chronic schizophrenic patients with long‐acting fluphenazine: double‐blind placebo trial
10. Control trial of depot fluphenazine in outpatient schizophrenics
11. Drug and sociotherapy in the aftercare of schizophrenic patients: one year relapse rates
12. Schizophrenics fully remitted on neuroleptics for 3–5 years: to stop or continue drugs?
13. Fluphenazine versus placebo in patients with remitted, acute first‐episodes of schizophrenia
14. Once weekly pimozide versus fluphenazine decanoate as maintainence therapy in chronic schizophrenia
15. Double‐blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients
16. Low dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates.
17. Dose response relationships in maintenance drug treatment for schizophrenia
18. Costs and benefits of two dosed of fluphenazine.
19. The Northwick Park study of first episodes of schizophrenia . II. A randomized controlled trial of prophylactic neuroleptic therapy
20. Drugs and rehabilitation in schizophrenia
21. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics.
22. Clinical and social comparison of fluphenazine decanoate and flupenthioxol decanoate in the community maintenance therapy of schizophrenialnt
23. A comparative controlled trial of pimozide and fluphenazine decanoate in continuation therapy of schizophrenia
24. Long‐acting oral versus injectable antipsychotic drugs in schizophrenics: a one‐year double‐blind comparison in multiple episode schizophrenics
25. The Collaborative Study Group. Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two year relapse rate
26. Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analyses of a two‐year controlled study of fluphenazine decanoate and fluphenazine hydrochloride
27. Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia
28. Prevention of relapse in schizophrenia: an evaluation of fluphenazine decanoate
29. Discontinuation or reduction of chemotherapy in chronic schizophrenics
30. Drug and family therapy in the aftercare of acute schizophrenics
31. Low and conventional dose maintenance therapy with fluphenazine decanoate: two year outcome
32. Family psychoeducation social skills training and maintenance chemotherapy in the aftercare treatment of schizophrenia. I. One year effects of a controlled study on relapse and expressed emotion.
33. Relapse in schizophrenia
34. Intermittent medication for stable schizophrenic outpatients: an alternative maintenance medication
35. Early intervention vs. continued pharmacotherapy of schizophrenia
36. Intermittent pharmacotherapy of schizophrenialn
37. Methylphenidate challenge as a predictor of relapse in schizophrenia
38. Provocations of schizophrenic symptoms by intravenous administration of methylphenidate
39. Methylphenidate, dextroamphetamine and levamphetamine effects on schizophrenic symptoms
40. Responses to apomorphine, amphetamine and neuroleptics in schizophrenic subjects
41. Amphetamine response and relapse risk after depot neuroleptic discontinuation
42. Drug discontinuation among long‐term successfully maintained schizophrenic outpatients
43. The duration of maintenance therapy in chronic schizophrenia
44. Do schizophrenics well adapted in the community need nueroleptics? A depot neuroleptic withdrawal study
45. Further observations on the duration of depot neuroleptic maintenance therapy in schizophrenia
46. A depot neuroleptic withdrawal study: a controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthioxol decanoate in chronic schizophrenic patients
47. Neuroleptic induced superseasitivity psychosis: clinical and pharmacologic characteristics
48. When, what and why? Psychopharmacology and other treatments in schizophrenia
49. A survey of drug‐induced extrapyramidal reactions
50. Tardive dyskinesia: prevalence and risk factors
51. Antischizophrenic drugs.
52. Acute dystonia induced by neuroleptic drugs
53. Are prophylactic antiparkinsonian drugs necessary? A controlled study of procyclidine withdrawal
54. Why do schizophrenic patients refuse to take their drugs?